Ads
related to: hcv polymerase inhibitors for diabetes management- Risks Of Hepatitis C
Read About The Risks Of Hep C And
Explore A Hep C Treatment Here.
- Hep C Treatment Info
Ready To Treat Your Hep C?
Learn About A Treatment Option Here
- Patient Support Program
Looking For Financial Assistance &
Insurance Support? Learn More Here.
- Find A Hep C Provider
Ready To Take The Next Step? Find
A Hep C Provider Near You Today!
- Download A Co-Pay Coupon
Eligible Patients May Pay As Little
As $5 Per Co-Pay For A Treatment
- Talk To Your Provider
Download A Conversation Guide And
Learn About A Treatment Option Here
- Risks Of Hepatitis C
Search results
Results From The WOW.Com Content Network
HCV genome. Nonstructural protein 5B (NS5B) is a viral protein found in the hepatitis C virus (HCV). [1] It is an RNA-dependent RNA polymerase, having the key function of replicating HCV's viral RNA by using the viral positive RNA strand as a template to catalyze the polymerization of ribonucleoside triphosphates (rNTP) during RNA replication.
The virus is internalized and the nucleocapsid is released into the cytoplasm of the hepatocyte after binding with the receptor. The NS5B protein, which is an RNA-dependent RNA polymerase, catalyzes hepatitis C virus replication. [10] The hepatitis C virus can cause acute infection but most patients are asymptomatic upon exposure.
The HCV genome. NS5A in the bottom row, second from the right. Nonstructural protein 5A (NS5A) inhibitors are direct acting antiviral agents (DAAs) that target viral proteins, and their development was a culmination of increased understanding of the viral life cycle combined with advances in drug discovery technology.
It is also possible that NS5A is a critical component during HCV replication and subcellular localization, which may shed light on the poorly understood HCV life cycle. [ 1 ] [ 4 ] Additionally, NS5A has been shown to modulate the polymerase activity of NS5B , an RNA-dependent RNA polymerase (RdRp) . [ 3 ]
The first protease inhibitor approved by the U.S. Food and Drug Administration (FDA). Ritonavir: Norvir: AbbVie: U.S. patent 5,541,206: March 1, 1996: AbbVie was part of Abbott Laboratories when patent was granted. As well as being a protease inhibitor in its own right, ritonavir inhibits the breakdown of other protease inhibitors.
The hepatitis C virus (HCV) [3] is a small (55–65 nm in size), enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. The hepatitis C virus is the cause of hepatitis C and some cancers such as liver cancer ( hepatocellular carcinoma , abbreviated HCC) and lymphomas in humans.
Ads
related to: hcv polymerase inhibitors for diabetes management